Societe Generale Asset Management
VC Fund
Paris, France
Societe Generale Asset Management is a VC fund in Paris focused on Biotechnology and Software. SGAM AI is a leading institutional player in Alternative Investment Management. SGAM AI successfully mixes the cultures of asset management and capital markets. They are client driven and institutional, like an asset manager. Their approach of each market is entrepreneurial and financial, like an investment bank. They offer the widest coverage ofAlternative Investment classes. Their size and profitability allow long term investments and credibility. They have the ability to offer solutions, not only products. SG Group's strengths are brought to the Alternative Investment's industry. They benefit from SG Group's long term commitment in Alternative Investments. They use the processes ans resources of SGAM Group (rated M2 by Fitch).
- Total investments:
- 47
- Last investment:
- Lead investor:
- 11%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Societe Generale Asset Management invests in
Stages Societe Generale Asset Management invests in
Countries Societe Generale Asset Management invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $1.9M–$55M
- Series B
- $2.1M–$15M
Investment Focus
Industry
- Biotechnology 14 (30%)
- Software 9 (19%)
- Health Care 7 (15%)
- Therapeutics 6 (13%)
- Information Technology 6 (13%)
Stage
- Series B 12 (26%)
- Funding Round 10 (21%)
- Series A 8 (17%)
- Series C 8 (17%)
- Series D 5 (11%)
Country
- France 19 (40%)
- United States 10 (21%)
- Germany 1 (2%)
- Hungary 1 (2%)
- Switzerland 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Werner Slavik
Head of Aviation
|
Head of Aviation | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| FORCE-A designs, produces, and sells optical sensors for the assessment of physiological and health status of crops. It offers crop sensors for nondestructive assessment of leaf polyphenolics. The company also provides multiparameter noncontact sensors-based on leaves or fruits, and berries autofluorescence measurements. Its multiparameternoncontact sensor provides inputs for decision support systems for a range of crops, including fertilisation needs, weed infestation, crop diseases, and crop yield and quality forecast. The company was founded in 2004 and is based in Orsay, France. | $2.1M / Series B / Nov 09, 2009 | ||
| Metrixware has, since 1995, been providing software maintenance & quality management solutions to CIOs and IT professionals through its System Code range of application management tools. The company provides global organizations with information, indicators and diagnostic to streamline decision making and implement best practice and compliancestandards. | $2M / Oct 31, 2008 | ||
| Augure by Launchmetrics' software and social data help brands and agencies to bridge the gap between traditional PR and Influencer Marketing. Every day, more than 1,000 Communication, PR, and Public Affairs teams use the Publisher platform to engage relevant influencers, manage their campaigns, improve efficiency and increase their presence inthe media and on social networks.The Augure by Launchmetrics' data services team compliments the Publisher software as the people behind the technology, offering consulting services that help clients to make sense of the data and apply it to their Influencer Marketing strategies.Founded in 2002 in Paris, Augure operates in Europe and Latin America. Its clients include Orange, Thales, AG Insurance, Pierre & Vacances, Château de Versailles, Amalthea, Hill+Knowlton and many others that span across the corporate sector. | $8.8M / Series D / Sep 30, 2008 | ||
| Genomic Vision is a biotechnology company that combines pioneering Molecular Combing, a proprietary single DNA molecule detection technology, with biomarker discovery to develop and commercialize novel genetic tests and research tools for life sciences.Genomic Vision’s products focus on DNA analysis and genetic testing in the fields ofcancer, rare inherited disorders and pharmacogenomics. | $4.4M / Series B / Jul 25, 2008 | ||
| Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases. | $4M / Series A / May 05, 2008 | ||
| Jobpartners - http://www.jobpartners.com provides software solutions for People Relationship Management. Covering the employee lifecycle through selection, talent and performance management, through enterprise social networking, to compensation management and appraisals. The company raising VC for the first time in 2000, and to datehas attracted over £35 million of financing. Today, Jobpartners has a strong position in the European marketplace as well as customers in North America and across the rest of the world. | $12.1M / Series C / Apr 01, 2008 | ||
| Adocia operates as a biotechnology company specializing in tissue regeneration. Adocia was founded in 2005 as Proteins & Peptides Management S.A.S. and changed its name to Adocia in January 2008. Adocia is based in Lyons, France. | $13.2M / Jan 21, 2008 | ||
| Arterial Remodeling Technologies SA engages in developing bioresorbable peripheral and coronary polymer stents that promote the natural remodeling of an injured artery after angioplasty. The company was founded in 2002 and is based in Noisy le Roi, France. | $6M / Nov 12, 2007 | ||
| Ekinops is a provider of next-generation optical transport solutions for service providers and private networks. Its carrier-grade solutions leverage expertise in 10G transmission, aggregation and Forward Error Correction (FEC) to allow operators to cost-effectively increase data transport capacity over dark fiber, CWDM, DWDM, SONET/SDH, IPand SAN networks. | $20M / Series B / Oct 01, 2007 | ||
| GQ Life Sciences, Inc. is a global life science information and search company. Formerly known as GenomeQuest, Inc., they changed their name in September of 2015 to highlight the fact that the product GenomeQuest has become a well-known brand within the industry. GQ Life Sciences is proud to offer its second major product, LifeQuest, alongside itsflagship GenomeQuest software. | $4M / Series B / Sep 24, 2007 | ||
| See all 47 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Societe Generale Asset Management invest in?
Societe Generale Asset Management invests primarily in Biotechnology, Software and Health Care startups, most often at Series B and Funding Round stage. Most of the 47 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Societe Generale Asset Management's check size?
Societe Generale Asset Management typically joins rounds of $1.9M–$55M at Series A and $2.1M–$15M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Societe Generale Asset Management participates in.
How do I contact Societe Generale Asset Management?
Public channels for Societe Generale Asset Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Societe Generale Asset Management?
The team at Societe Generale Asset Management includes Werner Slavik (Head of Aviation). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
